FIREBRICK Pharma is looking for volunteers to participate in paid clinical trials in researching a remedy for the common cold.<\/p>\n
The trial will study the effects of nasal spray Nasodine with participants receiving either active treatment or a placebo.<\/p>\n
Ballarat is among the first to test the medication, and Firebrick Pharma\u2019s executive chairman Dr Peter Molloy said it presents the chance to be part of a potential medical breakthrough.<\/p>\n
\u201cWe believe Nasodine will be a first-in-class nasal spray medicine in that it actually targets the viral cause of the common cold, where colds start, in the nose,\u201d he said.<\/p>\n
\u201cVictorian residents can be among the first in the world to try Nasodine, which in previous clinical trials has been shown to be safe and well-tolerated.<\/p>\n
\u201cThis trial seeks to confirm the efficacy of Nasodine as a treatment for the common cold.\u201d<\/p>\n
Nasodine uses the same active ingredient, povidone-iodine, as another one of Dr Molloy\u2019s products, Betadine Sore Throat Gargle.<\/p>\n
The trial will be delivered by Barwon Health\u2019s Adrian Costa Clinical Trials Centre through UFS Dispensaries.<\/p>\n
Participants will be required for one appointment, continuing nasal spray treatment independently for five days alongside two weeks of electronic reporting.<\/p>\n
Those who\u2019ve had cold symptoms for under 36 hours will be eligible to join the trial.<\/p>\n
To register, visit bit.ly\/3bxikPN.<\/p>\n","protected":false},"excerpt":{"rendered":"
FIREBRICK Pharma is looking for volunteers to participate in paid clinical trials in researching a remedy for the common cold. The trial will study the effects of nasal spray Nasodine with participants receiving either active treatment or a placebo. Ballarat is among the first to test the medication, and Firebrick Pharma\u2019s executive chairman Dr Peter […]<\/p>\n